-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Stock symbol
-
VRTX
-
Transactions as of
-
May 15, 2025
-
Transactions value $
-
-$22,084
-
Form type
-
4
-
Date filed
-
5/19/2025, 05:07 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| ALTSHULER DAVID |
EVP, Chief Scientific Officer |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
2025-05-19 |
0001550395 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Sale |
-$22.1K |
-52 |
-0.22% |
$424.69 |
23.3K |
May 15, 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: